Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on healthrelated quality of life

Authors Marc Miravitlles, Carles Llor, Jesús Molina, et al

Published Date January 2010 Volume 2010:5 Pages 11—19

DOI http://dx.doi.org/10.2147/COPD.S8732

Published 15 January 2010

Marc Miravitlles1, Carles Llor2, Jesús Molina3, Karlos Naberan4, Josep M Cots5, Fernando Ros6 on behalf of the EVOCA Study Group

1Fundació Clínic. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Ciber de Enfermedades Respiratorias (CIBERES), Barcelona, Spain; 2Primary Health Care Center ‘Jaume I’, Societat Catalana de Medicina Familiar i Comunitària, Universitat Rovira i Virgili, Tarragona, Spain; 3Primary Health Care Center ‘Francia’, Grupo de Respiratorio de la Sociedad Madrileña de Medicina Familiar y Comunitaria, Madrid, Spain; 4Primary Health Care Center ‘Fuentes de Ebro’, Grupo de Investigación del Instituto Aragonés Ciencias de la Salud (IACS), Zaragoza, Spain; 5Primary Health Care Center ‘La Marina’, Societat Catalana de Medicina Familiar i Comunitària, Facultat de Medicina, Barcelona, Spain; 6Medical Department, Bayer Healthcare, Barcelona, Spain

Objective: To investigate the impact of exacerbations in health-related quality of life (HRQL) of patients with COPD and to compare the effect of treatment of COPD exacerbations with moxifloxacin (400 mg/day for 5 days) and amoxicillin/clavulanate (500/125 mg 3 times a day for 10 days) on HRQL.

Methods: 229 outpatients with stable COPD (mean age 68.2 years; mean FEV1 % predicted 49.3%) participated in a prospective, observational study of 2 years’ duration. The St George’s Respiratory Questionnaire (SGRQ) was completed at baseline and every 6 months thereafter.

Results: COPD exacerbations (mean 2.7 episodes/patient) occurred in 136 patients (124 patients received the study medications [amoxicillin/clavulanate 54, moxifloxacin 70]). Differences between baseline and the final visit were higher for moxifloxacin compared with amoxicillin/clavulanate for total SGRQ score (-2.60 [13.1] vs 4.21 [16.2], P = 0.05) and “Symptoms” subscale (-5.64 [16.7] vs 8.27 [21], P = 0.02). The same findings were observed in patients with two or more exacerbations.

Conclusions: In COPD outpatients, treatment of exacerbations with moxifloxacin had a more favorable long-term effect on quality of life than amoxicillin/clavulanate.
Keywords: COPD, exacerbations, moxifloxacin, amoxicillin/clavulanate, quality of life, SGRQ

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Geographic differences in clinical characteristics and management of COPD: the EPOCA study

Marc Miravitlles, Cristina Murio, Gema Tirado-Conde, Gur Levy, Hana Muellerova, et al

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:803-814

Published Date: 15 September 2008

Readers of this article also read:

Metastatic medullary thyroid cancer: a dramatic response to a systemic chemotherapy (temozolomide and capecitabine) regimen

Lacin S, Esin E, Karakas Y, Yalcin S

OncoTargets and Therapy 2015, 8:1039-1042

Published Date: 13 May 2015

Fabrication of genistein-loaded biodegradable TPGS-b-PCL nanoparticles for improved therapeutic effects in cervical cancer cells

Zhang H, Liu G, Zeng X, Wu Y, Yang C, Mei L, Wang Z, Huang L

International Journal of Nanomedicine 2015, 10:2461-2473

Published Date: 27 March 2015

Transcatheter arterial chemoembolization with gemcitabine and oxaliplatin for the treatment of advanced biliary tract cancer

Zhao Q, Qian S, Zhu L, Qu XD, Zhang W, Yan ZP, Cheng JM, Liu QX, Liu R, Wang JH

OncoTargets and Therapy 2015, 8:595-600

Published Date: 9 March 2015

Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery

Vasconcelos A, Vega E, Pérez Y, Gómara MJ, García ML, Haro I

International Journal of Nanomedicine 2015, 10:609-631

Published Date: 27 January 2015

Ag-plasma modification enhances bone apposition around titanium dental implants: an animal study in Labrador dogs

Qiao SC, Cao HL, Zhao X, Lo HW, Zhuang LF, Gu YX, Shi JY, Liu XY, Lai HC

International Journal of Nanomedicine 2015, 10:653-664

Published Date: 14 January 2015

Effect of nanofiber content on bone regeneration of silk fibroin/poly(ε-caprolactone) nano/microfibrous composite scaffolds

Kim BS, Park KE, Kim MH, You HK, Lee J, Park WH

International Journal of Nanomedicine 2015, 10:485-502

Published Date: 9 January 2015

Molecular photoacoustic imaging of breast cancer using an actively targeted conjugated polymer

Balasundaram G, Ho CJH, Li K, Driessen WH, Dinish US, Wong CL, Ntziachristos V, Liu B, Olivo M

International Journal of Nanomedicine 2015, 10:387-397

Published Date: 8 January 2015

Does food insufficiency in childhood contribute to dementia in later life?

Momtaz YA, Haron SA, Hamid TA, Ibrahim R, Masud J

Clinical Interventions in Aging 2015, 10:49-53

Published Date: 17 December 2014